

**Reference List 2020-  
No. 559 -****2020**

- (559) Ahern TP, Collin LJ, Baurley JW, Kjærsgaard A, Nash R, Maliniak ML, Damkier P, Zwick ME, Isett RB, Christiansen PM, Ejlersen B, Lauridsen KL, Christensen KB, Silliman RA, Toft Sørensen H, Tramm T, Hamilton-Dutoit S, Lash TL, Cronin Fenton D. Metabolic pathway analysis and effectiveness of tamoxifen in Danish breast cancer patients. *Cancer Epidemiology Biomarkers Prev* 2020;29(3):582-590.
- (560) Ahern TP, Damkier P, Feddersen S, Kjærsgaard A, Lash TL, Hamilton-Dutoit S, Lythjohan CB, Ejlersen B, Christiansen PM, Cronin-Fenton DP. Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin. *Acta Oncol.* 2020;59(9):1009-1015. doi: 10.1080/0284186X.2020.1759820.
- (561) Ammitzboll G, Andersen KG, Bidstrup PE, Johansen C, Lanng C, Kroman N, et al. Effect of progressive resistance training on persistent pain after axillary dissection in breast cancer: a randomized controlled trial. *Breast Cancer Res Treat.* 2020;179(1):173-183.
- (562) Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, et al. Consortium of Investigators of Modifiers of BRCA and BRCA2. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genet Med.* 2020;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x.
- (563) Bens A, Dehlendorff C, Friis S, Cronin-Fenton D, Jensen MB, Ejlersen B, Lash TL, Kroman N, Mellemkjær L. The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study. *Br J Cancer.* 2020;122:1102-1108.
- (564) Berg T, Jensen MB, Jakobsen EH, Al-Rawi S, Kenholm J, Andersson M. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG). *The Breast* 2020; 54:242:247.
- (565) Christensen CØ, Jensen MB, Hermann AP, Ewertz M. Osteoporosis after adjuvant treatment for early-stage breast cancer. *Dan Med J* 2020;67(11):A04200223
- (566) Christensen T, Berg T, Nielsen LB, Andersson M, Jensen M, Knoop AS. Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients. *The Breast* 2020; 51:34-39.
- (567) Christensen TD, Buhl ASK, Christensen IJ, Buhl IK, Balslev E, Knoop AS, Danø H, Glavicic V, Luczak A, Langkjer ST, Linnet S, Jakobsen EH, Bogovic J, Ejlersen B, Rasmussen A, Hansen A, Knudsen S, Jensen PB, Nielsen D. Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective- prospective evaluation of the predictive potential of a multigene expression assay. *Breast Cancer.* 2020;27(2):266-276. doi: 10.1007/s12282-019-01017-7.
- (568) Collin LJ, Ulrichsen SP, Ahern TP, Goodman M, McCullough LE, Waller, LA, Christensen KB, Damkier P, Hamilton-Dutoit S, Lauridsen KL, Yacoub R, Christiansen P, Ejlersen B, Sørensen HT, Cronin-Fenton DP, Lash TL. 17 $\beta$ -Hydroxysteroid Dehydrogenase 1:2 and Breast Cancer Recurrence: A Danish Population-Based Study. *Acta Oncol.* 2020;59(3):329-333.

- (569) Falstie-Jensen, AM, Esen, BÖ, Kjærsgaard, A, Lorenzen, EL, Jensen, JD, Reinertsen, KV, Dekkers, OM, Ewertz, M, Cronin-Fenton, DP. Incidence of hypothyroidism after treatment for breast cancer—a Danish matched cohort study. *Breast Cancer Research* 2020;22(1):106.
- (570) Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, et al Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genet Epidemiol.* 2020;44(5):442-468.
- (571) Finnegan R, Lorenzen EL, Dowling J, Jensen I, Berg M, Thomsen MS, Delaney GP, Koh ES, Thwaites D, Brink C, Offersen BV, Holloway L. Analysis of cardiac substructure dose in a large, multi-centre danish breast cancer cohort (the DBCG HYPO trial): Trends and predictive modelling. *Radiother Oncol.* 2020;153:130-138.
- (572) Hauerslev KR, Madsen AH, Overgaard J, Damsgaard TE, Christiansen P. Long-term follow-up on shollder and arm morbidity in patients treated for early breast cancer. *Acta Oncol* 2020; 59: 851-58. doi 10.1080/0284186X.2020.1745269.
- (573) Heeg, E, Jensen, MB, Mureau, MAM, Ejlertsen, B, Tollenaar, RAEM, Christiansen, PM, Vrancken Peeters, MTFD. Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands. *Breast Cancer Research and Treatment* 2020;182(3):709-718.
- (574) Heeg E, Jensen MB, Hölmich LR, Bodilsen A, Tollenaar RAEM, Lænkholm AV, Offersen BV, Ejlertsen B, Mureau MAM, Christiansen PM. Rates of re-excision and conversion to mastectomy after breast-conserving surgery with or without oncoplastic surgery: a nationwide population-based study. *BJS* 2020;107(13):1762-72.
- (575) Jensen M, Lænkholm A, Balslev E, Buckingham W, Ferree S, Glavicic V, Jensen JD, Knoop AS, Mouridsen HT, Nielsen D, Nielsen TO, Ejlertsen B. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. *npj Breast Cancer* 2020. doi: 10.1038/s41523-020-0148-0
- (576) Kanstrup C, Teilum D, Rejmark L, Bigaard JV, Eiken P, Kroman N, et al. 25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival. *Breast Cancer Res Treat.* 2020;179(3):699-708.
- (577) Lorenzen EL, Rehammar CJ, Jensen MB, Ewertz M, Brink C. Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977-2005. *Radiother Oncol.* 2020;152:103-110.
- (578) Lænkholm A, Jensen MB, Eriksen JO, Roslind A, Buckingham W, Ferree S, Nielsen TO, Ejlertsen B. Population-based study of Prosigna-PAM50 and outcome among postmenopausal women with estrogen receptor positive and HER2 normal operable invasive lobular and ductal breast cancer. *Clinical Breast Cancer* 2020;20(4):e423-e432. \_
- (579) Mejdahl MK, Wohlfahrt J, Holm M, Knoop AS, Tjønneland A, Melbye M, Kroman N, Balslev E. Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology. *Breast Cancer Res Treat* 2020;182(1):229-238.
- (580) Milo MLH, Offersen BV, Bechmann T, Diederichsen ACP, Hansen CR, Holtved E, Josipovic M, Lörincz T, Maraldo MV, Nielsen MH, Nordmark M, Nyström PW, Pøhl M, Rose HK, Schytte T, Yates ES, Lorenzen EL. Delineation of whole heart and substructures in thoracic radiation therapy: National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups. *Radiother Oncol.* 2020;150:121-127.

- (581) Munck F, Clausen EW, Balslev E, Kroman N, Tvedskov TF, Holm-Rasmussen EV. Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. *Br J Surg.* 2020;107(1):96-102.
- (582) Møller T, Andersen C, Lillelund C, Bloomquist K, Christensen KB, Ejlertsen B, Tuxen M, Oturai P, Breitenstein U, Kolind C, Travis P, Bjerg T, Rørth M, Adamsen L. Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial. *Sci Rep.* 2020;10(1):9710. doi: 10.1038/s41598-020-66513-9.
- (583) Olafsdottir EJ, Borg A, Jensen MB, Gerdes A-M, Johansson ALV, Barkardottir RB, Johannsson OT, Ejlertsen B, Sønderstrup IMH, Hovig E, Lænkholm AV, Hansen TvO, Olafsdottir GH, Rossing M, Jonasson JG, Sigurdsson S, Loman N, Nilsson MP, Narod SA, Tryggvadottir, L. Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status. *British Journal of Cancer* 2020; 123:1608-1615.
- (584) Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, Stenbygaard L, Mjaaland I, Schreiber A, Kasti UM, Overgaard J; Danish Breast Cancer Group Radiation Therapy Committee. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. *J Clin Oncol* 2020;38(31):3615-3625.
- (585) Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J, et al. Association of Genomic Domains in *BRCA1* and *BRCA2* with Prostate Cancer Risk and Aggressiveness. *Cancer Res.* 2020;80(3):624-638.
- (586) Poikonen-Saksela P, Lindman H, Sverrisdottir A, Edlund P, Villman K, Tennvall Nittby L, Cold S, Bechmann T, Stenbygaard L, Ejlertsen B, Andersson M, Blomqvist C, Bergh J, Ahlgren J. Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1. *Acta Oncol.* 2020;59(7):825-832. doi: 10.1080/0284186X.2020.1757149.
- (587) Poulsen PR, Thomsen MS, Hansen R, Worm E, Spejlborg H, Offersen B. Fully automated detection of heart irradiation in cine MV images acquired during breast cancer radiotherapy. *Radiother Oncol* 2020;152:189-195.
- (588) Rose M, Svensson H, Handler J, Hoyer U, Ringberg A, Manjer J. Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer. *Breast Cancer Res Treat.* 2020;180:247–256.
- (589) Saltbæk L, Horsboel TA, Offersen BV, Andersson M, Friberg AS, Skriver SK, Bidstrup PE, Overgaard J, Johansen C, Dalton SO. Patterns in detection of recurrence among patients treated for breast cancer. *Breast Cancer Res Treat.* 2020;184(2):365-373.
- (590) Silvestri V, Leslie G, Barnes DR; CIMBA Group, Agnarsson BA, Aittomäki K, et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncol.* 2020; 6(8):1218-1230.
- (591) Skriver SK, Jensen MB, Knoop AS, Ejlertsen B, Laenkholm AV. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. *Breast Cancer Res* 2020;22(1):46. <https://doi.org/10.1186/s13058-020-01285-8>
- (592) Skriver SK, Jensen MB, Eriksen J-O, Ahlborn LB, Knoop AS, Rossing M, Ejlertsen B, Laenkholm AV. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients. *Breast Cancer Res Treat* 2020; 184:123-133.

- (593) Zarrizi R, Higgs MR, Voßgröne K, Rossing M, Bertelsen B, Bose M, Kousholt AN, Rösner H, Network TC, Ejlersen B, Stewart GS, Nielsen FC, Sørensen CS. Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability. *J Clin Invest*. 2020;130(8):4069-4080. doi:10.1172/JCI127521.
- (594) Zøylner IA, Kirkegaard P, Christiansen PM, Lomborg K. Patient involvement in the development of the Danish surgical breast cancer patient pathway – An action research project. *Action Research* 2020; doi. 10.1177/147650320960819.
- (595) Verholt AB, Foss ACH, Christiansen P, Lietzen LW. Non-surgically treated older women with operable early breast cancer in Denmark. *Dan Med J* 2020;67(11): A04200226.
- (596) Vogsen M, Bille C, Jylling AMB, Jensen MB, Ewertz, M. Adherence to treatment guidelines and survival in older women with early-stage breast cancer in Denmark 2008–2012. *Acta Oncol* 2020; 59(7):741-747.

## 2021

- (597) Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M; Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Ann Oncol*. 2021;32(10):1216-1235.
- (598) Celik A, Berg T, Knoop AS, Andersson M. Targeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly. *Ugeskr Laeger*. 2021;183(26):V12200938. PMID: 34219638.
- (599) Chan A, Moy B, Mansi J, Ejlersen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. *Clin Breast Cancer*. 2021;21(1):80-91.e7.
- (600) Collin LJ, Cronin-Fenton D, Ahern TP, Goodman M, McCullough LE, Waller LA, Kjærsgaard A, Damkier P, Christiansen P, Ejlersen B, Jensen MB, Sorensen HT, Lash, TL. Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women. *Clinical Cancer Research* 2021;27(5):1421-1428.
- (601) Early Breast Cancer Trialists' Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. *Lancet Oncol*. 2021;22(8):1139-1150.
- (602) Hjorth CF, Damkier P, Ejlersen B, Lash T, Sørensen HT, Cronin-Fenton D. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark. *BMC Med*. 2021;19(1):235. doi: 10.1186/s12916-021-02108-z.
- (603) Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlersen B, Yang EH, Glaspy JA, Slamon DJ. A careful reassessment of anthracycline use in curable breast cancer. *NPJ Breast Cancer*. 2021;7(1):134. doi: 10.1038/s41523-021-00342-5.
- (604) Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, Giobbie-Hurder A, Gelber RD, Ejlersen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Goldhirsch A, Di

- Leo A, Colleoni M, Vaz-Luis I, Lin NU. Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. *Cancer*. 2021;127(5):700-708.
- (605) Jørgensen N, Hviid TVF, Nielsen LB, Sønderstrup IMH, Eriksen JO, Ejlersen B, Gerdes AM, Kruse TA, Thomassen M, Jensen MB, Lænkholm AV. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. *Br J Cancer* 2021; 125(10):1388-1398.
- (606) Nielsen AWM, Kristensen MH, Offersen BV, Alsner J, Zachariae R, Nielsen HM. Patient-reported outcomes in postmenopausal breast cancer survivors - comparisons with normative data. *Acta Oncol*. 2021;60(1):78-86.
- (607) Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlersen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Ruepp B, Castiglione M, Coates AS, Gelber RD, Goldhirsch A, Colleoni M, Thürlimann B, Regan MM. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. *Breast Cancer Res Treat*. 2021;185:697–707.
- (608) Rossing M, Pedersen CB, Tvedskov T, Vejborg I, Talman ML, Olsen LR, Kroman N, Nielsen FC, Jensen MB, Ejlersen B. Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status. *Sci Rep* 2021; 11:2259. DOI: 10.1038/s41598-021-81538-4.
- (609) Stovgaard ES, Asleh K, Riaz N, Leung S, Gao D, Nielsen LB, Lænkholm AV, Balslev E, Jensen MB, Nielsen D, Nielsen TO. The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. *Oncol Immunology* 2021;10:1. DOI: 10.1080/2162402X.2021.1924492
- (610) Thomsen MS, Berg M, Zimmermann S, Lutz CM, Makocki S, Jensen I, Hjelstuen MHB, Pensold S, Hasler MP, Jensen MB, Offersen BV. Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial. *Clin Transl Radiat Oncol* 2021; 6(28):118-123.
- 2022**
- (611) Appelgren M, Sackey H, Wengström Y, Johansson K, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Rydén L, Sund M, Alkner S, Offersen BV, Tvedskov TF, Christiansen P, de Boniface J, on behalf of the SENOMAC Trialists' Group, Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial, *The Breast*. 2022;63:16-23.
- (612) Bose M, Benada J, Thatte JV, Kinalis S, Ejlersen B, Nielsen FC, Sørensen CS, Rossing M. A catalog of curated breast cancer genes. *Breast Cancer Res Treat*. 2022;91(2):431-441.
- (613) Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlersen B. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. *J Natl Cancer Inst*. 2022;114(10):1347-1354.
- (614) Celik A, Berg T, Nielsen LB, et al. First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG. *Breast Cancer: Basic and Clinical Research*. 2022;16.DOI: 10.1177/11782234221086992
- (615) Fuglsang Jensen M, Stick LB, Høyer M, Kronborg CJS, Lorenzen EL, Mortensen HR, Nyström PW, Petersen SE, Randers P, Thai LMH, Yates ES, Offersen BV. Proton therapy for early breast

- cancer patients in the DBCG Proton trial: planning, adaptation, and clinical experience from the first 43 patients. *Acta Oncol.* 2022;61(2):223-230.
- (616) Gottschau M, Bens A, Friis S, Cronin-Fenton D, Aalborg GL, Jensen MB, Ejlertsen B, Kroman N, Mellekjær L. Use of beta-blockers and risk of contralateral breast cancer. *Int J Cancer.* 2022;150(10):1619-1626.
- (617) Hassing CMS, Mejdahl MK, Lænkholm AV, Kroman N, Knoop AS, Tvedskov TF: Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors  $\leq 10$  mm: a nationwide study. *Breast Cancer Res Treat.* 2022;196(1):197-206.
- (618) Kavan S, Kruse TA, Vogsen M, Hildebrandt MG, Thomassen M. Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review. *Cancer Metastasis Rev.* 2022;41(2):433-446.
- (619) Lauritzen AD, Rodríguez-Ruiz A, von Euler-Chelpin MC, Lyng E, Vejborg I, Nielsen M, Karssemeijer N, Lillholm M. An Artificial Intelligence-based Mammography Screening Protocol for Breast Cancer: Outcome and Radiologist Workload. *Radiology.* 2022;304(1):41-49.
- (620) Røsevold, A.H., Andresen, N.K., Bjerre, C.A. et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. *Nat Med.* 2022;28:2573–2583.
- (621) Naghavi-Behzad M, Vogsen M, Vester RM, Olsen MMB, Oltmann H, Braad PE, Asmussen JT, Gerke O, Vach W, Kidholm K, Kodahl AR, Weber W, Hildebrandt MG. Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT. *Br J Cancer.* 2022;126(9):1271-1279.
- (622) Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Stenbygaard L, Pedersen AN, Thomsen MS, Yates E, Berg M, Lorenzen EL, Jensen I, Josipovic M, Jensen MB, Overgaard J; Danish Breast Cancer Group Radiotherapy Committee. Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial. *J Clin Oncol.* 2022;40(36):4189-4197
- (623) Overgaard M, Nielsen HM, Tramm T, Højris I, Grantzau TL, Alsner J, Offersen BV, Overgaard J; DBCG Radiotherapy Group. Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial. *Radiother Oncol.* 2022;170:4-13.
- (624) Pedersen RN, Esen BÖ, Mellekjær L, Christiansen P, Ejlertsen B, Lash TL, Nørgaard M, Cronin-Fenton D. The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis. *J Natl Cancer Inst.* 2022;114(3):391-399.
- (625) Shenasa E, Stovgaard ES, Jensen MB, Asleh K, Riaz N, Gao D, Leung S, Ejlertsen B, Lænkholm AV, Nielsen TO. Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. *Cancers (Basel).* 2022;14(15):3808. doi: 10.3390/cancers14153808.
- (626) Thomsen MS, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Møller M, Pedersen AN, Yates E, Berg M, Lorenzen E, Jensen I, Josipovic M, Overgaard J, Offersen BV; DBCG RT Committee. Volume matters: Breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial. *Radiother Oncol.* 2022;117:231-5.

- (627) Thorsen LBJ, Overgaard J, Matthiessen LW, Berg M, Stenbygaard L, Pedersen AN, Nielsen MH, Overgaard M, Offersen BV; DBCG Radiotherapy Committee. Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study. *J Clin Oncol*. 2022;40(36):4198-4206.
- (628) Viuff JH, Greiber IK, Karlsen MA, Storgaard L, Kroman N, Jensen MB, Eibye S, Hjortshøj CS, Ejlersen B, Winther JF, Kjær SK, Mellekjær L. Survival in Women Diagnosed With Breast Cancer During Pregnancy. *Clin Breast Cancer*. 2022;22(4):e517-e525. doi: 10.1016/j.clbc.2021.11.009.

## 2023

- (629) Artzi D, Berg T, Celik A, Kümler I, Kenholm J, Al-Rawi S, Jensen MB, Andersson M, Knoop A. Real-world survival of Danish patients with HER2-positive metastatic breast cancer. *Acta Oncol*. 2023;62(6):601-607. doi: 10.1080/0284186X.2023.2224926. PMID: 37338513.
- (630) Celik A, Berg T, Jensen MB, Jakobsen E, Nielsen HM, Kümler I, Glavicic V, Jensen JD, Knoop A. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer. *Breast Cancer* 2023;17:11782234231203292. doi: 10.1177/11782234231203292.
- (631) Depner JF, Berg T, Ejlersen B, Andreasen LW, Møller S, Maraldo MV. Treating brain metastases in metastatic breast cancer: outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis. *Acta Oncol*. 2023;62(11):1502-1510. doi: 10.1080/0284186X.2023.2260942.
- (632) Due A, Berg T, Jensen MB, Yammeni S, Volmer L, Brems-Eskildsen AS, Andersen KK, Rana S, Knoop A, Kümler I. A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients. *Acta Oncol* 2023;62(2):126-133. doi: 10.1080/0284186X.2023.2176257. PMID: 36929759.
- (633) Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. *Lancet*. 2023;402(10416):1991-2003. doi: 10.1016/S0140-6736(23)01082-6. PMID: 37931633.
- (634) Early Breast Cancer Trialists' Collaborative Group. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. *Lancet* 2023;401:1277-1292. doi: 10.1016/S0140-6736(23)00285-4. PMID: 37061269.
- (635) Garly R, Berg T, Jensen MB, Knoop a, Volmer l, Glavicic v, Khan H, Poulsen PB, Olsen J, Kümler I. A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark. *Acta Oncol* 2023;62(3):290-297. doi: 10.1080/0284186X.2023.2194030. PMID: 37010239.
- (636) Garly R, Knoop A, Jensen MB, Berg T, Nielsen HM, Kümler I. Atezolizumab and nab-paclitaxel for advanced breast cancer in Danish real-world patients. *Dan Med J*. 2023;70(9):A01230034. PMID: 37622644
- (637) Harborg S, Cronin-Fenton D, Jensen MR, Ahern TP, Ewertz M, Borgquist S. Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors. *JAMA Netw Open*. 2023;6(10):e2337780. doi:10.1001/jamanetworkopen.2023.37780. PMID: 37831449.

- (638) Hassing CMS, Mejdahl MK, Lænkholm AV, Kroman N, Knoop AS, Tvedskov THF. Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study. *Breast Cancer Res Treat.* 2023;198(1):103-112. doi: 10.1007/s10549-022-06839-2. PMID: 36576678.
- (639) Hjorth CF, Damkier P, Stage TB, Feddersen S, Hamilton-Dutoit S, Ejlertsen B, Lash TL, Bøggild H, Sørensen HT, Cronin-Fenton D. The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer. *Cancer Chemother Pharmacol.* 2023;91(2):157-165. doi: 10.1007/s00280-022-04499-z.
- (640) Holmes FA, Moy B, Delaloge S, Chia SKL, Ejlertsen B, Mansi J, Iwata H, Gnani M, Buysse M, Barrios CH, Silovski T, Šeparović R, Bashford A, Zotano AG, Denduluri N, Patt D, Gokmen E, Gore I, Smith JW 2nd, Loibl S, Masuda N, Tomašević Z, Petráková K, DiPrimeo D, Wong A, Martin M, Chan A; ExteNET Study Group. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. *Eur J Cancer.* 2023;184:48-59. doi: 10.1016/j.ejca.2023.02.002.
- (641) Jensen, MB., Pedersen, C.B., Misiakou, MA. et al. Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study. *npj Breast Cancer.* 2023;9(1):47. doi: 10.1038/s41523-023-00551-0. PMID: 37258527.
- (642) Lauritzen AD, Berg T, Jensen MB, Lillholm M, Knoop A. Identifying recurrent breast cancer patients in national health registries using machine learning. *Acta Oncol.* 2023;62(4):350-357. doi: 10.1080/0284186X.2023.2201687. PMID: 37074036.
- (643) Lynge E, Vejborg I, Lillholm M, Nielsen M, Napolitano G, von Euler-Chelpin M. Breast density and risk of breast cancer. *Int J Cancer.* 2023;152(6):1150-1158. doi: 10.1002/ijc.34316. PMID: 36214783.
- (644) Nielsen, K., Sode, M., Jensen, MB. et al. High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients. *Breast Cancer Res.* 2023;25(1):139. doi: 10.1186/s13058-023-01739-9. PMID: 37946261.
- (645) Refsgaard L, Skarsø ER, Ravkilde T, Nissen HD, Olsen M, Boye K, Laursen KL, Bekke SN, Lorenzen EL, Brink C, Thorsen LBJ, Offersen BV, Korreman SS. End-to-end framework for automated collection of large multicentre radiotherapy datasets demonstrated in a Danish Breast Cancer Group cohort. *Phys Imaging Radiat Oncol.* 2023;27:100485. doi:10.1016/j.phro.2023.100485. PMID: 37705727; PMCID: PMC10495662.
- (646) Reznitsky FM, Jensen JD, Knoop A, Jensen MB, Laenkholm AV. Evaluation of tumor-infiltrating lymphocytes, PD-L1, and PIK3CA mutations and association with prognosis in HER2-positive early stage breast cancer. *Acta Oncol.* 2023;62(12):1913-1920. doi: 10.1080/0284186X.2023.2279685. PMID: 37961947.
- (647) Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, Jensen JD, Asmussen JT, Jylling AMB, Braad PE, Vach W, Ewertz M, Hildebrandt MG. Response monitoring in metastatic breast cancer - a prospective study comparing <sup>18</sup>F-FDG PET/CT with conventional CT. *J Nucl Med.* 2023;64(3):355-361. doi: 10.2967/jnumed.121.263358. PMID: 36207136.

## 2024

- (648) Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, Bergkvist L, Frisell J, Olofsson Bagge R, Sund M, Christiansen P, Davide Gentilini O, Kontos M, Kühn T, Reimer T, Rydén L, Filtenborg Tvedskov T, Vrou Offersen B, Dahl Nissen H, de Boniface J; SENOMAC

- Trialists' Group. Quality assessment of radiotherapy in the prospective randomized SENOMAC trial. *Radiother Oncol.* 2024 Aug;197:110372. doi: 10.1016/j.radonc.2024.110372.
- (649) Andersen HH, Bojesen SE, Johansen JS, Ejlersen B, Berg T, Tuxen M, Madsen K, Danø H, Flyger H, Jensen MB, Nielsen DL. Prognostic Value of Pre-treatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer. *Cancer Epidemiol Biomarkers Prev.* 2024;33(5):662-670. doi: 10.1158/1055-9965.EPI-23-1299.
- (650) Berg T, Jensen MB, Rossing M, Bechmann T, Donskov D, Knoop AS, Ejlersen B.. Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer. *JAMA Netw Open.* 2024;7(3):e242174. doi:10.1001/jamanetworkopen.2024.2174
- (651) Berg T, Jensen MB, Celik A, Talman ML, Misiakou MA, Knoop AS, Nielsen FC, Ejlersen B, Rossing M. Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study. *JCI Insight* 2024;9(7):e178114. <https://doi.org/10.1172/jci.insight.178114>.
- (652) Berg T, Jensen MB, Rossing M, Axelsen CT, Kümler I, Søndergaard L, Vogsen M, Knoop AS, Ejlersen B. Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice . *Acta Oncol.* 2024;63(1):277–287. <https://doi.org/10.2340/1651-226X.2023.37270>
- (653) de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T; SENOMAC Trialists' Group. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. *Lancet Oncol.* 2024;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4.
- (654) de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists' Group; SENOMAC Trialists' Group. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. *N Engl J Med.* 2024;390(13):1163-1175. doi: 10.1056/NEJMoa2313487.
- (655) Buhl ES, Lorenzen EL, Refsgaard L, Nielsen AWM, Brixen ATL, Maae E, Holm HS, Schøler J, Thai LMH, Matthiessen LW, Maraldo MV, Nielsen MM, Johansen MB, Milo ML, Mogensen MB, Nielsen MH, Møller M, Sand M, Schultz P, Al-Rawi SA, Esser-Naumann S, Yammeni S, Petersen SE, Offersen BV, Korreman SS. Development and comprehensive evaluation of a national DBCG consensus-based auto-segmentation model for lymph node levels in breast cancer radiotherapy. *Radiother Oncol.* 2024;201:110567. doi: 10.1016/j.radonc.2024.110567.
- (656) Buhl ES, Refsgaard LH, Al-Rawi SA, Andersen K, Berg M, Boye K, Jensen I, Lorenzen EL, Maae E, Maraldo MV, Matthiessen LW, Milo ML, Nielsen MH, Saini A, Yates E, Offersen BV, Korreman SS. Population based audit of heart radiation doses in 6925 high-risk breast cancer patients from the Danish breast cancer group RT Nation study. *Radiother Oncol.* 2024;202:110643. doi: 10.1016/j.radonc.2024.110643.
- (657) Celik A, Berg T, Gibson M, Jensen MB, Kümler I, Eßer-Naumann S, Jakobsen EH, Knoop A, Nielsen D. Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer - a nationwide, retrospective study. *Acta Oncol.* 2024;63:494-502. doi: 10.2340/1651-226X.2024.38886.

- (658) Collin LJ, Waller LA, Cronin-Fenton DP, Ahern TP, Goodman M, McCullough LE, Kjærsgaard A, Woolpert KM, Silliman RA, Christiansen PM, Ejlertsen B, Sørensen HT, Lash TL. The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence: Application of the Trend-in-Trend Design. *Epidemiology*. 2024;35(5):660-666. doi: 10.1097/EDE.0000000000001753.
- (659) Gehrchen ML, Berg T, Garly R, Jensen MB et al. Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer. *BJC Rep* 2024;2: 64  
<https://doi.org/10.1038/s44276-024-00083-5>
- (660) Høgsbjerg KW, Maae E, Nielsen MH, Stenbygaard L, Pedersen AN, Yates E, Berg M, Lorenzen EL, Jensen I, Josipovic M, Thomsen MS, Offersen BV. Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial. *Radiother Oncol*. 2024 May;194:110195. doi: 10.1016/j.radonc.2024.110195.
- (661) Jensen AB, Christiansen P, Bech P, Zachariae B. Late effects following breast cancer treatment. *Ugeskr Laeger*. 2024 Mar 18;186(12):V02230091. Danish. doi: 10.61409/V02230091.
- (662) Lauritzen AD, Lillholm M, Lyng E, Nielsen M, Karssemeijer N, Vejborg I. Early Indicators of the Impact of Using AI in Mammography Screening for Breast Cancer. *Radiology*. 2024 Jun;311(3):e232479. doi: 10.1148/radiol.232479.
- (663) Levinson AKG, Dalton SO, Thygesen LC, Jakobsen E, Gögenur I, Borre M, Zachariae R, Christiansen P, Laurberg S, Christensen P, Hölmich LR, Brown PN, Johansen C, Kjær SK, van de Poll-Franse L, Kjaer TK. Cohort Profile: The Danish SEQUEL cohort. *Int J Epidemiol*. 2024 Feb 1;53(1):dyad189. doi: 10.1093/ije/dyad189.
- (664) Lund M, Corn G, Jensen MB, Petersen T, Dalhoff K, Ejlertsen B, Køber L, Wohlfahrt J, Melbye M. Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data. *Lancet Oncol*. 2024;25(11):1496-1506.  
[https://doi.org/10.1016/S1470-2045\(24\)00491-1](https://doi.org/10.1016/S1470-2045(24)00491-1).
- (665) Munck F, Jensen MB, Vejborg I, Gerlach MK, Maraldo MV, Kroman NT, Tvedskov THF. Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment: A Register-Based Study. *Ann Surg Oncol*. 2024 Aug;31(8):5157-5167. doi: 10.1245/s10434-024-15354-1
- (666) Nielsen AWM, Thorsen LBJ, Özcan D, Matthiessen LW, Maae E, Milo MLH, Nielsen MH, Tramm T, Overgaard J, Offersen BV. Internal mammary node irradiation in 4541 node-positive breast cancer patients treated with newer systemic therapies and 3D-based radiotherapy (DBCG IMN2): a prospective, nationwide, population-based cohort study. *Lancet Reg Health Eur*. 2024 Dec 12;49:101160. doi: 10.1016/j.lanep.2024.101160.
- (667) Nærum AW, Holm-Rasmussen EV, Vejborg I, Knoop AS, Lænkholm AV, Kroman N, Tvedskov TF. Locoregional Lymph Node Metastasis from Clinically Occult Breast Cancer: Prognostic Significance of Mastectomy. *Breast J*. 2024 Aug 9;2024:5878308. doi: 10.1155/2024/5878308.
- (668) Palshof FK, Mørch LS, Jensen MB, Storm HH, Kroman N, Tvedskov THF. Trends in breast cancer among elderly women: Development in estrogen and HER2 subtypes in the last ten years. *Breast*. 2024;79:103860. doi: 10.1016/j.breast.2024.103860.
- (669) Refsgaard L, Buhl ES, Nielsen AWM, Thomsen MS, Andersen K, Jensen I, Berg M, Lorenzen EL, Thorsen LBJ, Overgaard J, Korreman SS, Offersen BV; DBCG RT Committee. Quality assurance of internal mammary node irradiation in the DBCG IMN2 study. *Radiother Oncol*. 2024;202:110600. doi:10.1016/j.radonc.2024.110600.

- (670) Refsgaard L, Skarsø Buhl E, Yates E, Maae E, Berg M, Al-Rawi S, Saini A, Vestmø Maraldo M, Boye K, Louise Holm Milo M, Jensen I, Wichmann Matthiessen L, Nørring Bekke S, Holck Nielsen M, Laugaard Lorenzen E, Bech Jellesmark Thorsen L, Sofia Korreman S, Vrou Offersen B. Evaluating Danish Breast Cancer Group locoregional radiotherapy guideline adherence in clinical treatment data 2008-2016: The DBCG RT Nation study. *Radiother Oncol.* 2024;199:110289. doi: 10.1016/j.radonc.2024.110289.
- (671) Refsgaard L, Holm Milo ML, Buhl ES, Jensen JM, Maae E, Berg M, Jensen I, Nielsen MH, Lorenzen EL, Jellesmark Thorsen LB, Korreman SS, Offersen BV. The effect of coronary artery calcifications and radiotherapy on the risk of coronary artery disease in high-risk breast cancer patients in the DBCG RT-Nation cohort. *Radiother Oncol.* 2024:110705. doi: 10.1016/j.radonc.2024.110705.
- (672) Schmidt JA, Hjorth CF, Farkas DK, Damkier P, Feddersen S, Hamilton-Dutoit S, Ejlertsen B, Lash TL, Ahern TP, Cronin-Fenton D. Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study. *Breast Cancer Res Treat.* 2024 Sep 20. doi: 10.1007/s10549-024-07474-9.
- (673) Schmidt JA, Woolpert KM, Hjorth CF, Farkas DK, Ejlertsen B, Cronin-Fenton D. Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer. *J Clin Oncol.* 2024 Oct;42(28):3300-3307. doi: 10.1200/JCO.23.02643.
- (674) Skarping I, Bendahl PO, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Christiansen P, Filtenborg Tvedskov T, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Vrou Offersen B, Olofsson Bagge R, Reimer T, Sund M, Rydén L, de Boniface J. Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer. *JAMA Surg.* 2024 Dec 1;159(12):1393-1403. doi: 10.1001/jamasurg.2024.3944.
- (675) Sode M, Nielsen K, Jensen MB, Berg T, Knoop A, Ejlertsen B, Lænkholm AV. Survival outcomes for HER2-low breast cancer: Danish national data. *Acta Oncol.* 2024;63:878-886.
- (676) Søndergaard SR, Bechmann T, Maae E, Nielsen AWM, Nielsen MH, Møller M, Timm S, Lorenzen EL, Berry LL, Zachariae R, Offersen BV, Steffensen KD. Shared decision making with breast cancer patients - does it work? Results of the cluster-randomized, multicenter DBCG RT SDM trial. *Radiother Oncol.* 2024;193:110115. doi: 10.1016/j.radonc.2024.110115.
- (677) Tvedskov TF, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Bagge RO, Reimer T, Sund M, Rydén L, Christiansen P, de Boniface J; SENOMAC Trialists' Group. Axillary clearance and chemotherapy rates in ER+HER2-breast cancer: secondary analysis of the SENOMAC trial. *Lancet Reg Health Eur.* 2024 Sep 26;47:101083. doi: 10.1016/j.lanepe.2024.101083.
- (678) Thomsen MS, Alsner J, Lutz CM, Berg M, Jensen I, Lorenzen EL, Nielsen HM, Jakobsen EH, Stenbygaard L, Nielsen MH, Jensen MB, Overgaard J, Offersen BV; DBCG RT Committee. Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost. *Radiother Oncol.* 2024;201:110574. doi: 10.1016/j.radonc.2024.110574.
- (679) Torpe EM, Berg T, Jensen MB, Ejlertsen B. Compliance with Danish guidelines for adjuvant endocrine therapy among breast cancer survivors. *Dan Med J* 2024;71(12):A05240316. doi: 10.61409/A05240316
- (680) Woolpert KM, Schmidt JA, Ahern TP, Hjorth CF, Farkas DK, Ejlertsen B, Collin LJ, Lash TL, Cronin-Fenton DP. Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients. *Breast Cancer Res.* 2024 Apr 8;26(1):59. doi: 10.1186/s13058-024-01819-4.

**2025**

- (681) Berg T, Ahlborn L, Jensen MB, Knoop AS, Ejlersen B, Rossing M. Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer. *Neoplasia* 2025;63:101162. doi: 10.1016/j.neo.2025.101162.
- (682) Borgquist S, Jensen MB, Bendorff CL, Christiansen P, Offersen BV, Kodahl AR, Ewertz M, Jensen AB, Ahern TP, Cronin-Fenton D, Ejlersen B. Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo. *Clin Epidemiol.* 2025;17:409-419
- (683) Hassing CMS, Tvedskov THF, Kroman N, Knoop AS, Lænkholm AV. Evaluating the Prognostic Role of the PAM50 Signature and Selected Immune-Related Signatures for Recurrence in Patients With T1abN0 Breast Cancer. *Clin Breast Cancer.* 2025 Jan;25(1):e71-e78.e2. doi: 10.1016/j.clbc.2024.08.003
- (684) Jacobsen IC, Berg T, Jensen MB, Knop AS. Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study. *Acta Oncol.* 2025;64:1531-1539.
- (685) Jensen MB, Balslev E, Knoop AS, Tuxen MK, Højris I, Jakobsen EH, Cold S, Danø H, Glavicic V, Kenholm J, Ejlersen B. Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial. *J Clin Oncol.* 2025 Feb;43(4):373-380. doi: 10.1200/JCO.24.00836.
- (686) Jensen MB, Nielsen TO, Bartlett J, Lænkholm AV, Shepherd L, Ejlersen B. Prosigna Risk of Recurrence score and intrinsic subtypes as predictive markers for benefit of adjuvant anthracycline-based chemotherapy in high-risk breast cancer. *npj Breast Cancer* 2025;11(1):26. doi: 10.1038/s41523-025-00738-7.
- (687) Jensen MB, Torpe E, Teunissen Z, Taarnhøj G, Brix E, Knoop A, Yammeni S, Donskov F, Ejlersen B. Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group. *Lancet Oncol* 2025;26(5):654-662.
- (688) Jensen S, Tvedskov TF, Bechmann T, Tramm T, Jensen MB, Rahr HB, Lautrup MD. Additional Axillary Disease After Neoadjuvant Chemotherapy for Patients with Clinically Node-Negative but Sentinel Node-Positive Disease. *Ann Surg Oncol* 2025. doi: 10.1245/s10434-025-18045-7.
- (689) Kostov AM, Jensen MB, Ejlersen B, Thomassen M, Rossing CM, Pedersen IS, Petersen AH, Christensen LL, Wadt KAW, Lænkholm AV. Germline BRCA testing in Denmark following invasive breast cancer: Progress since 2000. *Acta Oncol* 2025;64:147-155.
- (690) Kostov AM, Jensen MB, Ejlersen B. et al. Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study. *Breast Cancer Res Treat.* 2025;212, 309-323.
- (691) Lund, M., Corn, G., Jensen, MB. et al. Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer. *Eur J Epidemiol* (2025). doi: [10.1007/s10654-025-01228-7](https://doi.org/10.1007/s10654-025-01228-7)
- (692) Misiakou MA, Jensen, MB, Talman ML Ejlersen B, Rossing M. Enhancing HER2-low breast cancer detection with quantitative transcriptomics. *npj Breast Cancer* 2025;11,98. doi: [10.1038/s41523-025-00817-9](https://doi.org/10.1038/s41523-025-00817-9)

- (693) Munck, F., Jensen, MB., Hawaz-ali, R. et al. Oncologic First Events in Breast Cancer Patients After Targeted Axillary Dissection. *Ann Surg Oncol* (2025). doi: [10.1245/s10434-025-18068-0](https://doi.org/10.1245/s10434-025-18068-0)
- (694) Thomsen MS, Lorenzen EL, Alsner J, Krogh SL, Yates ES, Berg M, Dypvik KI, Boye K, Kirkove C, Jensen I, Nielsen MMB, Tømmerås V, Schilling P, Makocki S, Hasler MP, Andersen K, Stick L, Jensen MB, Offersen BV. Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1. *Radiotherapy and Oncology* 2025;202 doi: [10.1016/j.radonc.2025.111142](https://doi.org/10.1016/j.radonc.2025.111142).